Long-term alopecia and bowel-disease studies report findings in continuing patients
Sun Pharma’s LEQSELVI update describes longer-term findings from an open-label extension.

Edivro Industry · Analysis based on the primary sources linked in this article.
Sun Pharma’s LEQSELVI update describes longer-term findings from an open-label extension. Sanofi and Teva’s duvakitug update reports maintenance-stage results among patients who responded in an earlier study. The treatments and diseases differ, but participant selection is important to interpreting both releases.
An extension can show how responses develop among people continuing treatment. It does not automatically reproduce the conditions of a new blinded comparison or establish the response expected for everyone starting a medicine.
Are these two treatments being compared?
No. They concern different indications and study programmes. Their response measures cannot be used to rank one against the other. The comparison concerns how to read sponsor-reported evidence, rather than relative clinical effectiveness.
What should a study headline retain?
The treatment’s regulatory status, study design and relevant patient population belong beside the result. Duvakitug is described as investigational. The LEQSELVI report addresses an extension of a separate programme. Distinguishing those features helps prevent a durability result from becoming an unsupported claim about all patients or an implied new approval.
Questions about this story
These answers summarise the article and refer to its original reporting period.
Are these two treatments being compared?
No. They concern different indications and study programmes. Their response measures cannot be used to rank one against the other. The comparison concerns how to read sponsor-reported evidence, rather than relative clinical effectiveness.
What should a study headline retain?
The treatment’s regulatory status, study design and relevant patient population belong beside the result. Duvakitug is described as investigational. The LEQSELVI report addresses an extension of a separate programme. Distinguishing those features helps prevent a durability result from becoming an unsupported claim about all patients or an implied new approval.
Publisher
Edivro Industry

